Pancreatic and Hepatic Oncology Research

Next-Generation Imipridones ONC206 and ONC212 Synergize with Lurbinectedin in Killing Pancreatic Ductal Adenocarcinoma Cells

This study shows that ONC206 and ONC212 synergize with lurbinectedin to kill pancreatic ductal adenocarcinoma cells with minimal toxicity to normal cells.

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer

This study identifies plectin as a biomarker of aggressive pancreatic cancer, showing it suppresses T cell activity and that targeting it with an antibody enhances anti-tumor immunity.

Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions

This study shows that CD44 deletion in pancreatic cancer-associated fibroblasts reduces tumor volume, alters their morphology and function, and enhances anti-tumor immune responses.

Invasion status stratifies the composition of the human pancreatic cancer perineural niche

Xenium and single-nucleus profiling of 14 human pancreatic tumors shows invaded nerve neighborhoods enriched for classical cancer cells, myCAFs and lipid-handling macrophages but depleted of lymphocytes.

Spatially Resolved Epithelial States Delineate Immunosuppressive Niches of Impaired Myeloid Antigen Presentation in PDAC

The paper identifies spatially distinct epithelial states in PDAC that correlate with immunosuppressive myeloid niches and poor prognosis.

Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer

The paper identifies periductal fibroblast density as a key factor in immune exclusion in pancreatic cancer, showing that CD44-dependent stromal checkpoints restrict leukocyte access to tumor epithelium.

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

This paper shows that pulsed narmafotinib priming improves chemotherapy response in pancreatic cancer by reducing fibrosis and enhancing treatment efficacy.

Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis

This study investigates how different KRAS mutations drive distinct phenotypic outcomes in pancreatic tumorigenesis, revealing mutation-specific oncogenic pathways and therapeutic implications.

Enterococcus faecalis is involved in the progression of the early stages of latent chronic pancreatitis surrounding pancreatic cancer tissue

The paper investigates the role of Enterococcus faecalis in the progression of latent chronic pancreatitis associated with pancreatic cancer tissue through pathological and serological analyses.

The basal cell state maintains pancreatic cancers by controlling an immunosuppressive circuit

This study identifies the basal cell state in pancreatic cancer as critical for maintaining tumors through an immunosuppressive circuit, showing its ablation leads to tumor collapse.

Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment

This study shows that combining stereotactic body radiation therapy with KRAS inhibition synergistically improves preclinical pancreatic cancer treatment by enhancing tumor control and reducing recurrence.

Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancer

This paper identifies two separable KRAS-combination partners in pancreatic cancer: an induced ERBB2/3 up-regulation and a standing FAK dependency, both computationally nominated from public data.

Spatial immune architecture and tumor lineage programs jointly shape clinical outcomes in advanced pancreatic ductal adenocarcinoma

This study combines spatial proteomics and transcriptomics in advanced PDAC to show that tumor lineage states and immune architecture are linked to clinical outcomes, with a new spatial immune score improving prognostic accuracy.

Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer

This study shows combination immunotherapy enhances systemic antitumor immunity induced by serial radiofrequency ablation in pancreatic cancer by targeting CD73, PD-L1, and CSF1R.

Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model

This study uses an in ovo model to show that the CAM platform supports tumor-stroma coevolution in pancreatic cancer, preserving patient-specific features and enabling functional analysis of stromal interactions.

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.

This study identifies a mechanism by which pancreatic fibrosis activates protumorigenic Schwann cells through nuclear mechanosensing involving c-Jun phosphorylation and Phospholipase A2.

Spatial analysis of Intraductal Papillary Mucinous Neoplasms reveals secretory cell-enriched neighborhoods

The paper uses spatial transcriptomics and immunostaining to analyze secretory cell distribution in IPMNs, finding spatial enrichment of specific cell types and associations with immune and fibroblast populations.

Early detection of pancreatic ductal adenocarcinoma by single-molecule profiling of pancreatic enzyme activities

This study develops a blood-based liquid biopsy platform using single-molecule enzyme activity profiling to detect pancreatic ductal adenocarcinoma with high specificity and moderate sensitivity across multiple stages.

Local delivery of SBRT and IL-12 to Murine PDAC Tumors Modulates Hematopoiesis

This study shows that local delivery of SBRT and IL-12 to PDAC tumors in mice affects bone marrow hematopoiesis, causing both acute and long-term changes.

A Luminal-Basal Stratification of the Native Human Pancreatic Duct is Differentially Represented in Pancreatic Cancers

This study identifies spatially distinct cell populations in human pancreatic ducts and shows that ASCP better preserves native cell identities compared to PDAC.

Overweight status drives early tumor microenvironment reprogramming in pancreatic ductal adenocarcinoma: a cell-type-resolved Bayesian hierarchical modeling and interactome analysis

This study identifies how overweight status reprograms the pancreatic tumor microenvironment through cell-type-specific changes using Bayesian modeling and interactome analysis.

Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22

This study shows antigen-presenting cancer-associated fibroblasts (apCAFs) in murine pancreatic tumors influence regulatory T cell phenotype and function through CXCL9 and CCL22, affecting immune checkpoint blockade response.

Detection of Pancreatic Cancer Using a Methylation-Specific PCR-Based Multi-Cancer Early Detection Test

This study evaluates EPISEEK-MCED, a blood-based test for detecting pancreatic cancer, showing high sensitivity and specificity across stages, with improved performance when combined with CA 19-9.

IL-1-activated cancer-associated fibroblasts promote STAT1-driven transcriptional reprogramming of pancreatic tumour cells

This paper shows that IL-1-activated cancer-associated fibroblasts (iCAFs) promote STAT1-driven transcriptional reprogramming in pancreatic tumour cells, leading to chemoresistance and identifying STAT1 as a therapeutic target.

eIF4G2-dependent translation restrains pancreatic cancer progression

This study identifies eIF4G2 as a translational checkpoint that restricts pancreatic cancer progression by maintaining epithelial identity and limiting metastasis.

GATA4 loss promotes mutant Kras-driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions

This study shows that GATA4 loss in Kras-mutant mice leads to PDAC without canonical precursor lesions, identifying a new lesion type and revealing GATA4's role in inflammatory programs.

CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma

This study identifies CA19-9's role in remodeling the PDAC tumor microenvironment by inducing IL1a and TGFb, leading to immunosuppressive changes that can be mitigated by blocking these factors.

A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer

This study identifies an opioid-mediated signaling axis in pancreatic cancer that drives extracellular matrix remodeling and tumor aggressiveness, suggesting methylnaltrexone as a potential therapeutic.

Extra-lineage tissue programs define the transcription states of human pancreatic cancer

The paper identifies four epithelial transcription states in pancreatic cancer and links their origins to early developmental processes.

The circadian gene Dec2 promotes pancreatic cancer dormancy by regulating tumor cell antigen presentation to facilitate immune evasion

This study identifies Dec2 as a circadian gene that promotes pancreatic cancer dormancy by reducing MHC-I antigen presentation, enabling immune evasion.